BRUNSWICK CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BRUNSWICK CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.36B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $5.24B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $6.40B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $6.81B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $5.85B | Feb 16, 2024 |
| FY2020 | Dec 31, 2020 | $1.16B | Feb 16, 2021 |
| FY2020 | Sep 26, 2020 | $1.23B | Feb 16, 2021 |
| FY2020 | Jun 27, 2020 | $987.80M | Feb 16, 2021 |
| FY2020 | Mar 28, 2020 | $965.50M | Feb 16, 2021 |
| FY2020 | Dec 31, 2019 | $917.60M | Feb 16, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.36B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $5.24B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $6.40B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $6.81B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $5.85B | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $4.35B | Feb 16, 2023 |
| FY2020 | Dec 31, 2019 | $4.11B | Feb 16, 2022 |
| FY2019 | Dec 31, 2018 | $4.12B | Feb 18, 2020 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.09B | Feb 20, 2018 |
| FY2017 | Sep 30, 2017 | $1.08B | Feb 20, 2018 |
| FY2017 | Jul 1, 2017 | $1.25B | Feb 20, 2018 |
| FY2017 | Apr 1, 2017 | $1.08B | Feb 20, 2018 |
| FY2017 | Dec 31, 2016 | $986.30M | Feb 20, 2018 |
| FY2017 | Oct 1, 2016 | $1.01B | Feb 20, 2018 |
| FY2017 | Jul 2, 2016 | $1.16B | Feb 20, 2018 |
| FY2017 | Apr 2, 2016 | $994.10M | Feb 20, 2018 |
| FY2016 | Dec 31, 2015 | $986.10M | Feb 17, 2017 |
| FY2016 | Oct 3, 2015 | $991.90M | Feb 17, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $336.30M | Feb 16, 2021 |
| FY2020 | Sep 26, 2020 | $376.90M | Feb 16, 2021 |
| FY2020 | Jun 27, 2020 | $256.00M | Feb 16, 2021 |
| FY2020 | Mar 28, 2020 | $243.80M | Feb 16, 2021 |
| FY2020 | Dec 31, 2019 | $236.60M | Feb 16, 2021 |
| FY2020 | Sep 28, 2019 | $276.90M | Feb 16, 2021 |
| FY2020 | Jun 29, 2019 | $328.00M | Feb 16, 2021 |
| FY2020 | Mar 30, 2019 | $279.50M | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $244.40M | Feb 18, 2020 |
| FY2019 | Sep 29, 2018 | $278.30M | Feb 18, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($137.30M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $130.10M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $420.40M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $677.00M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $593.30M | Feb 16, 2024 |
| FY2020 | Dec 31, 2020 | $95.10M | Feb 16, 2021 |
| FY2020 | Sep 26, 2020 | $137.90M | Feb 16, 2021 |
| FY2020 | Jun 27, 2020 | $70.70M | Feb 16, 2021 |
| FY2020 | Mar 28, 2020 | $69.00M | Feb 16, 2021 |
| FY2020 | Dec 31, 2019 | $67.10M | Feb 16, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($40.70M) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $311.60M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $734.90M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $947.80M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $812.90M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $539.30M | Feb 16, 2023 |
| FY2020 | Dec 31, 2019 | $471.00M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $355.50M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $330.30M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $479.50M | Feb 19, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $168.70M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $169.60M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $185.20M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $202.90M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $154.50M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $125.90M | Feb 16, 2023 |
| FY2020 | Dec 31, 2019 | $121.60M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $121.50M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $111.60M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $139.20M | Feb 19, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $851.10M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $747.90M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $812.20M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $771.40M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $697.80M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $543.70M | Feb 16, 2023 |
| FY2020 | Dec 31, 2019 | $509.60M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $515.20M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $458.10M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $598.10M | Feb 19, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $562.10M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $431.40M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $733.60M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $586.10M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $574.00M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $798.30M | Feb 16, 2023 |
| FY2020 | Dec 31, 2019 | $434.20M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $337.00M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $400.30M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $435.30M | Feb 19, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $165.80M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $167.40M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $289.30M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $388.30M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $267.10M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $182.40M | Feb 16, 2023 |
| FY2020 | Dec 31, 2019 | $232.60M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $180.20M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $178.00M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $193.90M | Feb 19, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.31B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $5.68B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $6.23B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $6.32B | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $5.43B | Feb 16, 2023 |
| FY2020 | Dec 31, 2020 | $3.77B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $3.56B | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $4.29B | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $3.36B | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $3.28B | Feb 20, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.63B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.89B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $2.09B | Feb 13, 2026 |
| FY2025 | Dec 31, 2022 | $2.04B | Feb 13, 2026 |
| FY2024 | Dec 31, 2021 | $1.91B | Feb 14, 2025 |
| FY2023 | Dec 31, 2020 | $1.51B | Feb 16, 2024 |
| FY2022 | Dec 31, 2019 | $1.30B | Feb 16, 2023 |
| FY2020 | Dec 31, 2018 | $1.58B | Feb 16, 2022 |
| FY2020 | Dec 31, 2017 | $1.48B | Feb 16, 2021 |
| FY2019 | Dec 31, 2016 | $1.44B | Feb 18, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $681.20M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $966.10M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $1.03B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $967.60M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $888.40M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $417.70M | Feb 16, 2023 |
| FY2020 | Dec 31, 2019 | $415.00M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $377.30M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $33.90M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $413.80M | Feb 19, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.36B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $3.61B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $3.60B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $3.29B | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $2.72B | Feb 16, 2023 |
| FY2020 | Dec 31, 2020 | $2.23B | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $1.93B | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $2.14B | Feb 18, 2020 |
| FY2018 | Jan 1, 2018 | $1.94B | Feb 19, 2019 |
| FY2018 | Dec 31, 2017 | $1.97B | Feb 19, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $256.80M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $269.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $467.80M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $595.60M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $354.50M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $519.60M | Feb 16, 2023 |
| FY2020 | Dec 31, 2019 | $320.30M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $294.40M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $448.80M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $422.40M | Feb 19, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.12B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.37B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $2.46B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $2.54B | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | $1.85B | Feb 16, 2023 |
| FY2020 | Dec 31, 2020 | $973.20M | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | $1.11B | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | $1.22B | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $437.40M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | $439.40M | Feb 20, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 9 | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 7 | Feb 16, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Feb 16, 2021 |
| FY2020 | Sep 26, 2020 | 1 | Feb 16, 2021 |
| FY2020 | Jun 27, 2020 | 0 | Feb 16, 2021 |
| FY2020 | Mar 28, 2020 | 0 | Feb 16, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 16, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 1 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 5 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 9 | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 7 | Feb 16, 2024 |
| FY2020 | Dec 31, 2020 | 1 | Feb 16, 2021 |
| FY2020 | Sep 26, 2020 | 1 | Feb 16, 2021 |
| FY2020 | Jun 27, 2020 | 0 | Feb 16, 2021 |
| FY2020 | Mar 28, 2020 | 0 | Feb 16, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 16, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 64.89M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 65.99M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | 68.23M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | 71.37M | Feb 16, 2024 |
| FY2022 | Dec 31, 2021 | 76.93M | Feb 16, 2023 |
| FY2020 | Dec 31, 2020 | 77.88M | Feb 16, 2022 |
| FY2020 | Dec 31, 2019 | 79.57M | Feb 16, 2021 |
| FY2019 | Dec 31, 2018 | 86.76M | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | 87.54M | Feb 19, 2019 |
| FY2017 | Dec 31, 2016 | 89.32M | Feb 20, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $112.60M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $112.30M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $112.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $108.60M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $98.90M | Feb 16, 2024 |
| FY2022 | Dec 31, 2020 | $78.30M | Feb 16, 2023 |
| FY2020 | Dec 31, 2019 | $73.40M | Feb 16, 2022 |
| FY2020 | Dec 31, 2018 | $67.80M | Feb 16, 2021 |
| FY2019 | Dec 31, 2017 | $60.60M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $55.40M | Feb 19, 2019 |